These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32392947)

  • 1. [Interpretation and analysis of the testing results of main molecular pathological markers in breast cancer].
    Yang YL; Guo XJ; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):526-528. PubMed ID: 32392947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
    Wu JT; Astill ME; Gagon SD; Bryson L
    J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
    Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
    Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results.
    Allison KH
    Surg Pathol Clin; 2018 Mar; 11(1):147-176. PubMed ID: 29413654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum c-erB-2 levels in monitoring of operable breast cancer patients.
    Imoto S; Kitoh T; Hasebe T
    Jpn J Clin Oncol; 1999 Jul; 29(7):336-9. PubMed ID: 10470658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers (c-erbB-2, p53) in breast cancer.
    Agrawal AK; Jeleń M; Rudnicki J; Grzebieniak Z; Zukrowski P; Nienartowicz E
    Folia Histochem Cytobiol; 2008; 46(4):449-55. PubMed ID: 19141397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker assessment and molecular testing for prognostication in breast cancer.
    Kos Z; Dabbs DJ
    Histopathology; 2016 Jan; 68(1):70-85. PubMed ID: 26768030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.
    Mabrouk RA; Ali-Labib R
    Clin Biochem; 2003 Oct; 36(7):537-43. PubMed ID: 14563447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of several biological markers in the prognosis of patients with node-negative breast cancer].
    Zhang B; Li Y; Ma T
    Zhonghua Zhong Liu Za Zhi; 2000 Jul; 22(4):298-300. PubMed ID: 11778554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer.
    Ratnakar N; Sharma BK; Chaturvedi KU; Kaur S; Naik SL; Ray A
    APMIS; 1998 Nov; 106(11):1075-80. PubMed ID: 9890270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
    Pinto AE; André S; Laranjeira C; Soares J
    Pathology; 2005 Feb; 37(1):45-50. PubMed ID: 15875733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
    Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
    Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
    Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
    Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers in Paget disease of the breast.
    Fu W; Lobocki CA; Silberberg BK; Chelladurai M; Young SC
    J Surg Oncol; 2001 Jul; 77(3):171-8. PubMed ID: 11455553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological markers of invasive breast cancer.
    Matsumoto A; Jinno H; Ando T; Fujii T; Nakamura T; Saito J; Takahashi M; Hayashida T; Kitagawa Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):99-105. PubMed ID: 26486826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei])].
    Sugano K; Kawai T; Ishii M; Koyama H; Kitajima M; Kasumi F; Demura R; Nakayama T; Okabe H; Mori S
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1255-62. PubMed ID: 7913313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Situ Hybridization of Breast Cancer Markers.
    Min L; Shou C
    Methods Mol Biol; 2016; 1406():53-9. PubMed ID: 26820944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.